Business Segments Kymera Therapeutics, Inc.
Equities
KYMR
US5015751044
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 80.20 USD | +2.64% |
|
-5.84% | +3.57% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||
Pharmaceuticals | 72.83M | 46.83M | 78.59M | 47.07M | 39.21M | |||
Total Assets | 606M | 603M | 576M | 978M | 1.74B | |||
Interest Expense | -175K | -176K | -196K | -249K | -370K | |||
CAPEX | -1.6M | -2.84M | -34.48M | -12.84M | -1.45M | |||
EBT | -100M | -155M | -147M | -224M | -311M | |||
D&A | 2.4M | 2.98M | 3.56M | 7.37M | 8.31M | |||
Operating Income | -101M | -161M | -166M | -262M | -349M | |||
Net Income | -100M | -155M | -147M | -224M | -311M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
United States | 72.83M | 46.83M | 78.59M | 47.07M | 39.21M | |||
Total Assets | 606M | 603M | 576M | 978M | 1.74B | |||
Interest Expense | -175K | -176K | -196K | -249K | -370K | |||
D&A | 2.4M | 2.98M | 3.56M | 7.37M | 8.31M | |||
CAPEX | -1.6M | -2.84M | -34.48M | -12.84M | -1.45M | |||
Net Income | -100M | -155M | -147M | -224M | -311M | |||
EBT | -100M | -155M | -147M | -224M | -311M | |||
Operating Income | -101M | -161M | -166M | -262M | -349M |
- Stock Market
- Equities
- KYMR Stock
- Financials Kymera Therapeutics, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition